Drug news
EU gives final approval for subcutaneous Herceptin
The European Commission has given final approval for a new subcutaneous formulation of Herceptin (trastuzumab), from Roche, for the treatment of HER2-positive Breast Cancer. Approval is based on results from the Phase III HannaH study.
The new subcutaneous formulation can be administered in less than five minutes, compared to 90 minutes with the intravenous formulation. The new formulation is approved for both early and later stage treatment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.